BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett's esophagus compared with the general population: a population-based cohort study. Gastroenterology 2013;144:1375-83, 1383.e1. [PMID: 23583429 DOI: 10.1053/j.gastro.2013.02.050] [Cited by in Crossref: 46] [Cited by in F6Publishing: 49] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 van der Ende-van Loon MCM, Stoker A, Nieuwkerk PT, Curvers WL, Schoon EJ. How are we measuring health-related quality of life in patients with a Barrett Esophagus? A systematic review on patient-reported outcome measurements. Qual Life Res 2021. [PMID: 34748137 DOI: 10.1007/s11136-021-03009-7] [Reference Citation Analysis]
2 Alkhayyat M, Kumar P, Sanaka KO, Thota PN. Chemoprevention in Barrett's esophagus and esophageal adenocarcinoma. Therap Adv Gastroenterol 2021;14:17562848211033730. [PMID: 34434254 DOI: 10.1177/17562848211033730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Weismüller J, Thieme R, Hoffmeister A, Weismüller T, Gockel I. Barrett-Screening: Rationale, aktuelle Konzepte und Perspektiven. TumorDiagnostik & Therapie 2021;42:345-353. [DOI: 10.1055/a-1466-9727] [Reference Citation Analysis]
4 Fisher OM, Chan DL, Talbot ML, Ramos A, Bashir A, Herrera MF, Himpens J, Shikora S, Higa KD, Kow L, Brown WA. Barrett's Oesophagus and Bariatric/Metabolic Surgery-IFSO 2020 Position Statement. Obes Surg 2021;31:915-34. [PMID: 33460005 DOI: 10.1007/s11695-020-05143-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
5 Höllwarth ME, Sorantin E. Gastroesophageal Reflux and Hiatal Hernia. Pediatric Surgery 2021. [DOI: 10.1007/978-3-662-43559-5_95] [Reference Citation Analysis]
6 Moayyedi P, El-Serag HB. Current Status of Chemoprevention in Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:117-30. [PMID: 33213791 DOI: 10.1016/j.giec.2020.08.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Grady WM, Yu M, Markowitz SD, Chak A. Barrett's Esophagus and Esophageal Adenocarcinoma Biomarkers. Cancer Epidemiol Biomarkers Prev 2020;29:2486-94. [PMID: 33093162 DOI: 10.1158/1055-9965.EPI-20-0223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
8 Triggs JR, Falk GW. Best Practices in Surveillance for Barrett's Esophagus. Gastrointest Endosc Clin N Am 2021;31:59-75. [PMID: 33213800 DOI: 10.1016/j.giec.2020.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kamboj AK, Katzka DA, Iyer PG. Endoscopic Screening for Barrett's Esophagus and Esophageal Adenocarcinoma: Rationale, Candidates, and Challenges. Gastrointest Endosc Clin N Am 2021;31:27-41. [PMID: 33213798 DOI: 10.1016/j.giec.2020.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
10 Tyselskyi VV, Bondarchuk BG, Hordovskyi VA, Kebkalo AB. Application of biological welding as a method of treatment of esophageal metaplasia. KH 2020;87:9-12. [DOI: 10.26779/2522-1396.2020.5-6.09] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Serha TV, Kuryk OH, Yakovenko VO, Tkachenko RP. RISK OF ADENOCARCINOMA IN BARRETT'S ESOPHAGUS. WOMAB 2020;16:120. [DOI: 10.26724/2079-8334-2020-1-71-120-124] [Reference Citation Analysis]
12 Höllwarth ME, Sorantin E. Gastroesophageal Reflux and Hiatal Hernia. Pediatric Surgery 2020. [DOI: 10.1007/978-3-642-38482-0_95-1] [Reference Citation Analysis]
13 Templeton A, Kaz A, Snider E, Grady WM. Barrett’s Esophagus: Diagnosis and Management. Esophageal Cancer 2020. [DOI: 10.1007/978-3-030-29832-6_4] [Reference Citation Analysis]
14 Maddalo G, Fassan M, Cardin R, Piciocchi M, Marafatto F, Rugge M, Zaninotto G, Pozzan C, Castoro C, Ruol A, Biasiolo A, Farinati F. Squamous Cellular Carcinoma Antigen Serum Determination as a Biomarker of Barrett Esophagus and Esophageal Cancer: A Phase III Study. J Clin Gastroenterol 2018;52:401-6. [PMID: 28422774 DOI: 10.1097/MCG.0000000000000790] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
15 Patel A, Gyawali CP. Screening for Barrett's Esophagus: Balancing Clinical Value and Cost-effectiveness. J Neurogastroenterol Motil 2019;25:181-8. [PMID: 30827080 DOI: 10.5056/jnm18156] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Nguyen AD, Spechler SJ, Dunbar KB. Barrett's Esophagus. Evidence-based Gastroenterology and Hepatology 4e 2019. [DOI: 10.1002/9781119211419.ch2] [Reference Citation Analysis]
17 Calabrese C, Salice M, Pagano N, Manta R, Rizzello F. Timing and Protocols of Clinical and Endoscopic Surveillance of Barrett’s Esophagus. Revisiting Barrett's Esophagus 2019. [DOI: 10.1007/978-3-319-92093-1_11] [Reference Citation Analysis]
18 Bar N, Schwartz N, Nissim M, Fliss-Isacov N, Zelber-Sagi S, Kariv R. Barrett’s esophagus with high grade dysplasia is associated with non-esophageal cancer. World J Gastroenterol 2018; 24(39): 4472-4481 [PMID: 30356981 DOI: 10.3748/wjg.v24.i39.4472] [Reference Citation Analysis]
19 Cook MB, Coburn SB, Lam JR, Taylor PR, Schneider JL, Corley DA. Cancer incidence and mortality risks in a large US Barrett's oesophagus cohort. Gut 2018;67:418-529. [PMID: 28053055 DOI: 10.1136/gutjnl-2016-312223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
20 Westerveld D, Khullar V, Mramba L, Ayoub F, Brar T, Agarwal M, Forde J, Chakraborty J, Riverso M, Perbtani YB, Gupte A, Forsmark CE, Draganov P, Yang D. Adherence to quality indicators and surveillance guidelines in the management of Barrett's esophagus: a retrospective analysis. Endosc Int Open 2018;6:E300-7. [PMID: 29507870 DOI: 10.1055/s-0044-101351] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
21 Masuda A, Fujita T, Murakami M, Yamazaki Y, Kobayashi M, Terao S, Sanuki T, Okada A, Adachi M, Shiomi H, Arisaka Y, Kutsumi H, Umegaki E, Azuma T. Influence of hiatal hernia and male sex on the relationship between alcohol intake and occurrence of Barrett's esophagus. PLoS One 2018;13:e0192951. [PMID: 29447244 DOI: 10.1371/journal.pone.0192951] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Richter JE. Editorial: maybe our 'Barrett's recommendation speech' should change? Aliment Pharmacol Ther 2017;45:1266-7. [PMID: 28370045 DOI: 10.1111/apt.14001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Britton J, Gadeke L, Lovat L, Hamdy S, Hawkey C, Mclaughlin J, Ang Y. Research priority setting in Barrett's oesophagus and gastro-oesophageal reflux disease. The Lancet Gastroenterology & Hepatology 2017;2:824-31. [DOI: 10.1016/s2468-1253(17)30250-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
24 Clerx E, Kupfer SS, Leffler DA; North American Society for the Study of Celiac Disease. Disparities Among Gastrointestinal Disorders in Research Funding From the National Institutes of Health. Gastroenterology 2017;153:877-80. [PMID: 28867278 DOI: 10.1053/j.gastro.2017.08.051] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Britton J, Keld R, Prasad N, Hamdy S, McLaughlin J, Ang Y. Effect of diagnosis, surveillance, and treatment of Barrett's oesophagus on health-related quality of life. Lancet Gastroenterol Hepatol 2018;3:57-65. [PMID: 28970029 DOI: 10.1016/S2468-1253(17)30213-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
26 Wani S, Gaddam S. Editorial: Best Practices in Surveillance of Barrett's Esophagus. Am J Gastroenterol 2017;112:1056-60. [PMID: 28725066 DOI: 10.1038/ajg.2017.117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
27 Erichsen R, Horvath-Puho E, Lund JL, Dellon ES, Shaheen NJ, Pedersen L, Davey Smith G, Sørensen HT. Mortality and cardiovascular diseases risk in patients with Barrett's oesophagus: a population-based nationwide cohort study. Aliment Pharmacol Ther 2017;45:973-82. [PMID: 28139003 DOI: 10.1111/apt.13962] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
28 Brücher BL, Li Y, Schnabel P, Daumer M, Wallace TJ, Kube R, Zilberstein B, Steele S, Voskuil JL, Jamall IS. Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers. Clin Transl Med 2016;5:13. [PMID: 27053248 DOI: 10.1186/s40169-016-0093-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
29 Theron BT, Padmanabhan H, Aladin H, Smith P, Campbell E, Nightingale P, Cooper BT, Trudgill NJ. The risk of oesophageal adenocarcinoma in a prospectively recruited Barrett's oesophagus cohort. United European Gastroenterol J 2016;4:754-61. [PMID: 28408992 DOI: 10.1177/2050640616632419] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
30 Labenz J, Labenz C. Prävalenz und natürlicher Verlauf der gastroösophagealen Refluxkrankheit. Gastroenterologe 2016;11:102-9. [DOI: 10.1007/s11377-016-0045-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
31 Small AJ, Falk GW. Selection of patients for cancer prevention and eradication. Esophageal cancer and barrett's esophagus 2015. [DOI: 10.1002/9781118655153.ch22] [Reference Citation Analysis]
32 Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, Shaheen NJ. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus. Gastroenterology 2015;149:1752-1761.e1. [PMID: 26327132 DOI: 10.1053/j.gastro.2015.08.048] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 8.0] [Reference Citation Analysis]
33 Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium. Gastroenterology 2015;149:1599-606. [PMID: 26296479 DOI: 10.1053/j.gastro.2015.08.007] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 9.3] [Reference Citation Analysis]
34 Pereira AD, Chaves P. Low risk of adenocarcinoma and high-grade dysplasia in patients with non-dysplastic Barrett's esophagus: Results from a cohort from a country with low esophageal adenocarcinoma incidence. United European Gastroenterol J 2016;4:343-52. [PMID: 27403300 DOI: 10.1177/2050640615612409] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
35 Yang Y, Chen H, Wang R, Tang Y, Chen X. Cost-Effectiveness Analysis on Endoscopic Surveillance Among Western Patients With Barrett's Esophagus for Esophageal Adenocarcinoma Screening. Medicine 2015;94:e1563. [DOI: 10.1097/md.0000000000001563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
36 Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, Vakil N, Sanders S, Vieth M, Inadomi J. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol. 2015;110:662-682; quiz 683. [PMID: 25869390 DOI: 10.1038/ajg.2015.55] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 12.7] [Reference Citation Analysis]
37 Falk GW. Barrett's oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol 2015;29:125-38. [PMID: 25743461 DOI: 10.1016/j.bpg.2015.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
38 Labenz J. Gastroösphageale Refluxerkrankung. SpringerReference Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_533-1] [Reference Citation Analysis]
39 Templeton A, Kaz A, Grady WM. Barrett’s Esophagus: Diagnosis and Management. Esophageal Cancer 2015. [DOI: 10.1007/978-3-319-20068-2_4] [Reference Citation Analysis]
40 Labenz J. Gastroösophageale Refluxerkrankung. DGIM Innere Medizin 2015. [DOI: 10.1007/978-3-642-54676-1_533-2] [Reference Citation Analysis]
41 Castaño Llano R, Alvarez O, Piñeres A, Ruíz Vélez MH, Rojas A, Alvarez Diazgranados A, Ruíz Velásquez LM, Restrepo D, Calvo Betancur VD. Evaluación de la eficacia de la terapia ablativa con argón plasma en el esófago de Barrett con displasia: seguimiento prospectivo no menor a un año. Rev Colomb Gastroenterol 2014;29:347-357. [DOI: 10.22516/25007440.422] [Reference Citation Analysis]
42 Brücher BL, Kitajima M, Siewert JR. Undervalued criteria in the evaluation of multimodal trials for upper GI cancers. Cancer Invest 2014;32:497-506. [PMID: 25250506 DOI: 10.3109/07357907.2014.958497] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
43 Tsibouris P, Hendrickse MT, Mavrogianni P, Isaacs PE. Ischemic heart disease, factor predisposing to Barrett’s adenocarcinoma: A case control study. World J Gastrointest Pharmacol Ther 2014; 5(3): 183-190 [PMID: 25133047 DOI: 10.4292/wjgpt.v5.i3.183] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
44 Gatenby P, Caygill C, Wall C, Bhatacharjee S, Ramus J, Watson A, Winslet M. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus. World J Gastroenterol 2014; 20(28): 9611-9617 [PMID: 25071359 DOI: 10.3748/wjg.v20.i28.9611] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
45 Triadafilopoulos G. Revis(it)ing Barrett's esophagus. Gastrointest Endosc 2014;79:574-6. [PMID: 24630083 DOI: 10.1016/j.gie.2013.11.007] [Reference Citation Analysis]
46 Butt J, Kandel G. Barrett esophagus: when to endoscope. Clin Endosc 2014;47:40-6. [PMID: 24570882 DOI: 10.5946/ce.2014.47.1.40] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
47 Falk GW. Update on ablation for Barrett's esophagus. Curr Gastroenterol Rep 2014;16:368. [PMID: 24357349 DOI: 10.1007/s11894-013-0368-7] [Reference Citation Analysis]
48 Shaheen NJ, Hur C. Garlic, silver bullets, and surveillance upper endoscopy for Barrett's esophagus. Gastroenterology 2013;145:273-6. [PMID: 23806540 DOI: 10.1053/j.gastro.2013.06.028] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]